Biochips Market Size, Growth, Share & Trends Analysis
Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region - Global Forecast to 2030
USD 21,356.4 MN
MARKET SIZE, 2030
CAGR 8.8%
(2025-2030)
350
REPORT PAGES
300
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biochips market, valued at US$12,907.5 million in 2024, stood at US$14,011.6 million in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2024 to 2030, culminating in a forecasted valuation of US$21,356.4 million by the end of the period. The growth of the biochips market is driven by the rising demand for personalized medicine and precision diagnostics, increasing adoption of biochips in genomics, proteomics, and drug discovery, and continuous technological advancements in microfluidics and lab-on-chip systems.
KEY TAKEAWAYS
-
The biochips market comprises instruments, consumables and software & services. Consumables was the largest segment because they are required for every test or assay, ensuring recurring demand. Their frequent use in research, diagnostics, and clinical applications drives consistent revenue and market dominance.
-
By type, the biochips market is segmented into DNA Chips, Lab-on-a-Chip, protein Chips, Tissue Arrays, and Cell Arrays. The Lab-on-a-Chip segment is projected to witness the highest CAGR throughout the forecast period, as it enables rapid, cost-effective, and portable testing by integrating multiple laboratory functions on a single microfluidic platform. Its ability to deliver quick, accurate results with minimal sample volumes is driving adoption in point-of-care diagnostics, drug discovery, and personalized medicine.
-
Key fabrication technologies include Microarrays and Microfluidics. The microarrays segment is expected to be the largest, mainly attributable to its wide usage in large-scale gene expression profiling, genotyping, and biomarker discovery. Its proven reliability, high throughput, and broad application in genomics and clinical research sustain its market dominance.
-
In the biochips market, biotechnology and pharmaceutical companies lead in demand because they rely heavily on biochips for drug discovery, genomic analysis, and biomarker research, enabling faster and more precise development of targeted therapies, followed by hospitals and diagnostic centers, academic & research institutes, contract research organizations (CROs), and other end users.
-
The biochips materials market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the biochips market due to its robust biotechnology and pharmaceutical sector, advanced research infrastructure, and substantial investment in genomics and personalized medicine. The presence of leading market players and early adoption of innovative diagnostic technologies further strengthen its dominance.
-
Major market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), and Agilent Technologies, Inc. (US) have entered into several agreements and partnerships to advance biochip technologies, expand their product portfolios, accelerate innovation in genomics, proteomics, and personalized diagnostics, and meet the growing global demand for high-throughput and precise diagnostic solutions.
The biochips market is witnessing steady growth, driven by the increasing prevalence of cardiac arrhythmias, rising adoption of advanced diagnostic and therapeutic devices, and growing awareness of heart health. New developments, including innovations in catheter-based ablation technologies, wearable monitoring devices, and strategic collaborations between medical device companies and healthcare providers, are reshaping the industry landscape.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on consumers’ businesses in the biochips market arises from evolving healthcare needs, technological innovation, and the shift toward personalized medicine. Pharmaceutical, biotechnology, and diagnostic companies are the primary users of biochip solutions, focusing on high-throughput analysis, rapid diagnostics, and precision research. The growing demand for faster, data-driven insights and cost-effective testing has a direct influence on R&D efficiency and clinical outcomes. These factors, in turn, drive the adoption of advanced biochip technologies and integrated analytical platforms, shaping the market’s growth trajectory.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Growing demand for personalized medicines
-
Technological advancements in microfluidics and AI integration
RESTRAINTS
Impact
Level
Level
-
High cost of biochip development and fabrication
-
Data management and standardization issues
OPPORTUNITIES
Impact
Level
Level
-
Expanding applications in point-of-care and decentralized diagnostics
-
Increasing government and private investments in genomics research
CHALLENGES
Impact
Level
Level
-
Technical complexity and integration of multidisciplinary technologies
-
Regulatory and validation hurdles for clinical use
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing demand for personalized medicines
The growing demand for personalized medicine is a key driver of the biochips market, as healthcare increasingly shifts toward tailored diagnostics and treatments based on individual genetic profiles. Biochips enable the rapid and high-throughput analysis of genes, proteins, and biomarkers, providing critical insights for personalized therapies and disease prevention. Their ability to support precise, data-driven decision-making in oncology, pharmacogenomics, and rare disease research is fueling widespread adoption across clinical and research settings.
Restraint: High cost of biochip development and fabrication
The high cost of biochip development and fabrication acts as a significant restraint on market growth. Producing biochips involves complex microfabrication processes, advanced materials, and precision instrumentation, all of which contribute to elevated manufacturing expenses. Additionally, high R&D costs, low yield rates, and the need for specialized infrastructure limit large-scale production and accessibility, particularly in emerging markets.
Opportunity: Expanding applications in point-of-care and decentralized diagnostics
Expanding applications in point-of-care and decentralized diagnostics present a significant opportunity for the biochips market. Lab-on-chip and microfluidic biochips enable rapid, accurate testing outside traditional laboratories, supporting real-time disease detection and monitoring in clinical, remote, and low-resource settings. Their portability, low sample requirements, and quick turnaround times are driving adoption in infectious disease testing, personalized medicine, and emergency care, aligning with the global shift toward accessible and preventive healthcare.
Challenge: Technical complexity and integration of multidisciplinary technologies
The technical complexity and integration of multidisciplinary technologies pose a key challenge in the biochips market. Developing functional biochips requires expertise in multiple disciplines, including microfluidics, nanotechnology, materials science, and bioinformatics, making the design and manufacturing process highly intricate. Ensuring seamless integration of biological, electronic, and analytical components while maintaining accuracy and reproducibility adds to development difficulty, often leading to longer timelines, higher costs, and scalability issues for commercial production.
Biochips Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Utilizes advanced microarray biochip technology designed for high-throughput genomic and transcriptomic analysis across research and clinical applications. | Enables parallel analysis of thousands of genes, enhances discovery efficiency, and supports large-scale genomic profiling with high reproducibility. |
 |
Offers a robust microarray platform integrated with sequencing workflows for genome-wide association studies and complex trait analysis. | Provides exceptional data accuracy, supports comprehensive genotyping and expression profiling, and accelerates translational research in precision medicine. |
 |
Employs microarray biochips to detect copy number variations, genetic mutations, and microRNA expression patterns with high resolution. | Facilitates precise genomic comparison and expression analysis, aids in identifying disease-associated variants, and improves diagnostic and oncology research accuracy. |
 |
Provides lab-on-chip modules for sample preparation, amplification and detection of nucleic acids in decentralized settings. | Simplifies sample workflow, lowers operator dependency, and enables point-of-care or near-patient diagnostics. |
 |
Leverages lab-on-a-chip microfluidic technology for automated sample handling, electrophoresis, and nucleic acid or protein analysis. | Streamlines laboratory workflows, minimizes sample and reagent use, and ensures rapid, high-precision analytical performance for research and quality control. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The ecosystem of the biochips market comprises a dynamic network of stakeholders that collectively drive innovation, product development, and adoption across research and clinical applications. At the core are key manufacturers such as Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which lead the development of advanced microarray, lab-on-chip, and microfluidic platforms. Supporting them are software and AI developers specializing in bioinformatics, data analytics, and automated interpretation, who often collaborate with biochip OEMs to integrate intelligent data processing and cloud-based solutions. Additionally, research institutions, pharmaceutical companies, and diagnostic laboratories play a vital role in validating and applying biochip technologies for genomics, proteomics, and personalized medicine.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Biochips Market, By Product & Service
As of 2024, consumables held the largest share of the biochips market because they are required for every test or experiment, ensuring consistent and recurring demand. These include reagents, substrates, and assay kits used in genomic, proteomic, and diagnostic applications. Their single-use nature, combined with the increasing volume of testing in research and clinical diagnostics, drives continuous consumption and revenue growth for manufacturers. Additionally, ongoing innovations in assay chemistry and customization for specific applications further strengthen their market dominance.
Biochips Market, By Type
In 2024, DNA Chips dominated the biochips market due to their widespread use in genomics, gene expression profiling, and genetic testing. They enable high-throughput analysis of DNA sequences, mutations, and polymorphisms, making them essential tools in research, diagnostics, and the discovery of new drugs. Their reliability, scalability, and cost efficiency have led to strong adoption across clinical and academic settings. Additionally, ongoing advancements in hybridization techniques and data analysis tools continue to enhance their performance and sustain market leadership.
Biochips Market, By Fabrication Technology
As of 2024, microarrays held the largest share of the biochips market due to their extensive use in genomics, proteomics, and biomarker research. They enable simultaneous analysis of thousands of biological interactions, allowing rapid and high-throughput gene expression and mutation studies. Their proven accuracy, scalability, and cost-effectiveness have made them indispensable in both clinical diagnostics and life science research. Additionally, continuous improvements in detection technologies and data analytics are further enhancing their utility and sustaining their dominant market position.
Biochips Market, By End User
The biotechnology and pharmaceutical companies segment is expected to dominate the biochips market, as they rely heavily on these technologies for drug discovery, genomic analysis, and biomarker identification. Biochips enable high-throughput screening, target validation, and personalized drug development, accelerating R&D and reducing costs. Their ability to generate precise molecular insights supports innovation in precision medicine and therapeutic development. Additionally, increasing investments in genomics research and advanced diagnostics by pharma and biotech firms continue to strengthen this segment’s market dominance.
REGION
Asia Pacific to be fastest-growing region in global biochips market during forecast period
The Asia Pacific biochips market is expected to register the highest CAGR during the forecast period, driven by rapid advancements in biotechnology, expanding healthcare infrastructure, and increasing government investments in genomics and precision medicine. Rising healthcare awareness, a growing middle-class population, and the presence of emerging biotech hubs in countries like China and India are driving demand for advanced diagnostic and research tools. Additionally, collaborations between global biochip manufacturers and regional research institutions are accelerating the adoption of technology and driving market growth across the region.
Biochips Market: COMPANY EVALUATION MATRIX
In the biochips market matrix, Thermo Fisher Scientific Inc. (Star) leads with a substantial market share and an extensive product portfolio, driven by its advanced microarray, lab-on-chip, and next-generation sequencing platforms widely adopted across research, clinical, and diagnostic applications. The company’s dominance is reinforced by its continuous R&D investments, global distribution network, and strong presence in genomics and proteomics workflows. Bio-Rad Laboratories, Inc. (Emerging Leader) is gaining recognition for its innovative biochip solutions and integrated analysis platforms, which enhance precision, reproducibility, and data interpretation in molecular research. While Thermo Fisher leads through scale and comprehensive solutions, Bio-Rad shows strong potential to advance toward the leaders’ quadrant as demand for high-performance, data-driven biochip technologies continues to accelerate.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- Illumina, Inc. (US)
- Agilent Technologies, Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- QIAGEN (Germany)
- Bio-Rad Laboratories, Inc. (US)
- Abbott (US)
- Standard BioTools Inc. (US)
- 10x Genomics (US)
- Cepheid (US)
- bioMérieux (France)
- Revvity (US)
- DiaSorin S.p.A. (Italy)
- Randox Laboratories Ltd. (UK)
- Oxford Gene Technology IP Limited (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 12,907.5 Million |
| Market Forecast in 2030 (Value) | USD 21,356.4 Million |
| Growth Rate | CAGR of 8.8% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million), Volume (Thousand Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: Biochips Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Comparison of leading biochip types: DNA Chips, Lab-on-a-Chip, Protein Chips, Tissue and Cell Arrays. DNA chips dominate due to their crucial role in genetic and genomic research, broad applicability in disease diagnostics, and continuous advancements improving hybridization efficiency and data accuracy. | Enables identification of product adoption shifts across care settings; Detects safety and compliance-related trends impacting purchasing. |
| Company Information | Key players: Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd and QIAGEN. Top 3-5 players market share analysis at APAC and European country level. | Provided insights on revenue transitions toward emerging applications such as personalized medicine, point-of-care testing, and drug discovery. |
| Geographic Analysis | Detailed analysis on Rest of APAC was provided to one of the top players. Client focused on ASEAN Market country level analysis for biochip adoption and localization strategies. | Supported country-level demand mapping to guide new product launches and regional manufacturing strategies. |
RECENT DEVELOPMENTS
- May 2025 : Agilent Technologies, Inc. opened its first India Solution Center at its LEED Platinum-certified Manesar office in Haryana. This new facility strengthens Agilent’s focus on India as a high-growth, innovation-driven market and will provide integrated solutions across the sectors it serves. The facility supports the development of analytical workflows, proof-of-concept demonstrations, collaborative research and development, and training.
- October 2024 : QIAGEN announced that the US FDA has cleared the QIAstat-Dx Respiratory Panel Mini for clinical use. The panel is designed to assist in diagnosing upper respiratory infections in outpatient settings, covering five common viral causes: influenza A, influenza B, human rhinovirus, respiratory syncytial virus (RSV), and SARS-CoV-2.
- April 2024 : Illumina, Inc. announced that DRAGEN Array, a bioinformatics software suite for analysis of Infinium microarray data, enhanced its functionality by enabling high-throughput and quantitative reporting of quality control (QC) metrics for Infinium methylation arrays.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
31
2
RESEARCH METHODOLOGY
37
3
EXECUTIVE SUMMARY
53
4
PREMIUM INSIGHTS
58
5
MARKET OVERVIEW
Biochip market surges with AI integration, personalized medicine, and emerging microfluidic technologies.
62
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
RISING ADOPTION OF PERSONALIZED MEDICINE
5.2.1.2
TECHNOLOGICAL ADVANCEMENTS IN MICROARRAY AND MICROFLUIDICS FABRICATION
5.2.1.3
INCREASING R&D INVESTMENTS IN GENOMICS AND PROTEOMICS
5.2.1.4
ADVANCEMENTS IN POINT-OF-CARE DIAGNOSTICS AND LAB-ON-A-CHIP TECHNOLOGIES
5.2.2
RESTRAINTS
5.2.2.1
HIGH COST OF INSTRUMENTS AND FABRICATION
5.2.2.2
COMPLEX DATA INTERPRETATION AND STANDARDIZATION
5.2.3
OPPORTUNITIES
5.2.3.1
INTEGRATION OF AI AND BIOINFORMATICS IN BIOCHIP DATA ANALYSIS
5.2.3.2
EXPANSION INTO EMERGING MARKETS AND NEW APPLICATIONS
5.2.4
CHALLENGES
5.2.4.1
TECHNICAL COMPLEXITY AND INTEGRATION OF MULTIDISCIPLINARY TECHNOLOGIES
5.2.4.2
REGULATORY AND VALIDATION HURDLES FOR CLINICAL USE
5.3
INDUSTRY TRENDS
5.3.1
MINIATURIZATION, PORTABILITY, AND DECENTRALIZED DIAGNOSTICS
5.3.2
SHIFT TOWARD MICROFLUIDICS AND LAB-ON-A-CHIP FORMATS
5.4
TECHNOLOGY ANALYSIS
5.4.1
KEY TECHNOLOGIES
5.4.1.1
DIGITAL MICROFLUIDIC BIOCHIPS
5.4.1.2
PLASMONIC AND NANOPLASMONIC BIOCHIPS
5.4.1.3
WEARABLE AND IMPLANTABLE BIOCHIPS
5.4.2
ADJACENT TECHNOLOGIES
5.4.2.1
AI/MACHINE LEARNING FOR BIOCHIP DATA & DESIGN
5.4.2.2
OPTICAL GENOME MAPPING CHIPS
5.4.3
COMPLEMENTARY TECHNOLOGIES
5.4.3.1
ADVANCED MICROFABRICATION AND 3D PRINTING
5.4.3.2
BIOCHIP INTEGRATION IN BIOSENSORS
5.5
PORTER’S FIVE FORCES ANALYSIS
5.5.1
THREAT OF NEW ENTRANTS
5.5.2
THREAT OF SUBSTITUTES
5.5.3
BARGAINING POWER OF SUPPLIERS
5.5.4
BARGAINING POWER OF BUYERS
5.5.5
INTENSITY OF COMPETITIVE RIVALRY
5.6
REGULATORY LANDSCAPE
5.6.1
REGULATORY ANALYSIS
5.6.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7
PATENT ANALYSIS
5.7.1
PATENT PUBLICATION TRENDS FOR BIOCHIPS
5.7.2
JURISDICTION AND TOP APPLICANT ANALYSIS
5.8
TRADE ANALYSIS
5.8.1
IMPORT DATA FOR HS CODE 9027
5.8.2
EXPORT DATA FOR HS CODE 9027
5.9
PRICING ANALYSIS
5.9.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.9.2
AVERAGE SELLING PRICE TREND, BY REGION
5.9.2.1
AVERAGE SELLING PRICE OF DNA CHIPS AND LAB-ON-A-CHIP, BY REGION
5.9.2.2
AVERAGE SELLING PRICE TREND OF DNA CHIPS, BY REGION
5.9.2.3
AVERAGE SELLING PRICE TREND OF LAB-ON-A-CHIP, BY REGION
5.9.2.4
AVERAGE SELLING PRICE TREND OF PROTEIN CHIPS, BY REGION
5.10
KEY CONFERENCES AND EVENTS, 2025–2026
5.11
KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2
BUYING CRITERIA
5.12
END-USER ANALYSIS AND UNMET NEEDS
5.13
IMPACT OF AI/GENERATIVE AI ON BIOCHIPS MARKET
5.13.1
INTRODUCTION
5.13.2
MARKET POTENTIAL IN BIOCHIPS ECOSYSTEM
5.13.3
AI-USE CASES
5.13.4
KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET
5.14
ECOSYSTEM ANALYSIS
5.15
CASE STUDY ANALYSIS
5.15.1
MICROFLUIDIC BIOCHIP-BASED MULTIPLEXED PROFILING FOR EARLY CANCER DETECTION
5.15.2
POINT-OF-CARE TUMOR MARKER DETECTION BIOCHIP
5.15.3
GRAPHENE QUANTUM DOT-BASED BIOCHIP FOR CHILDHOOD LEUKEMIA DETECTION
5.16
VALUE CHAIN ANALYSIS
5.17
SUPPLY CHAIN ANALYSIS
5.18
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.19
INVESTMENT AND FUNDING SCENARIO
5.20
US TARIFF IMPACT ON BIOCHIPS MARKET
5.20.1
INTRODUCTION
5.20.2
KEY TARIFF RATES
5.20.3
PRICE IMPACT ANALYSIS
5.20.4
IMPACT ON COUNTRY/REGION
5.20.5
IMPACT ON END-USE INDUSTRIES
5.20.5.1
BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
5.20.5.2
HOSPITALS AND DIAGNOSTIC CENTERS
5.20.5.3
ACADEMIC & RESEARCH INSTITUTES
5.20.5.4
CONTRACT RESEARCH ORGANIZATIONS (CROS)
5.20.5.5
OTHER END USERS
6
BIOCHIPS MARKET, BY PRODUCTS & SERVICES
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 8 Data Tables
109
6.1
INTRODUCTION
6.2
CONSUMABLES
6.2.1
SURGE IN APPLICATIONS ACROSS PERSONALIZED MEDICINE AND PRECISION DIAGNOSTICS TO AID GROWTH
6.3
INSTRUMENTS
6.3.1
RISING DEMAND FOR ADVANCED INSTRUMENTS TO ENHANCE PRECISION AND EFFICIENCY TO DRIVE MARKET
6.4
SOFTWARE & SERVICES
6.4.1
INCREASING NEED FOR ADVANCED DATA ANALYSIS AND BIOINFORMATICS TO SUPPORT GROWTH
7
BIOCHIPS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million and Units | 47 Data Tables
118
7.1
INTRODUCTION
7.2
DNA CHIPS
7.2.1
GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023–2030 (THOUSAND UNITS)
7.2.2
DNA CHIPS MARKET, BY APPLICATION
7.2.2.1
GENE EXPRESSION
7.2.2.2
SNP GENOTYPING
7.2.2.3
CANCER DIAGNOSTICS & TREATMENT
7.2.2.4
GENOMICS
7.2.2.5
DRUG DISCOVERY
7.2.2.6
AGRICULTURAL BIOTECHNOLOGY
7.2.2.7
OTHER DNA CHIP APPLICATIONS
7.3
LAB-ON-A-CHIP
7.3.1
GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023–2030 (THOUSAND UNITS)
7.3.2
LAB-ON-A-CHIP MARKET, BY APPLICATION
7.3.2.1
CLINICAL DIAGNOSTICS
7.3.2.2
GENOMICS
7.3.2.3
IVD & POC
7.3.2.4
PROTEOMICS
7.3.2.5
DRUG DISCOVERY
7.3.2.6
OTHER LOAC APPLICATIONS
7.4
PROTEIN CHIPS
7.4.1
GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023–2030 (THOUSAND UNITS)
7.4.2
PROTEIN CHIPS MARKET, BY APPLICATION
7.4.2.1
PROTEOMICS
7.4.2.2
EXPRESSION PROFILING
7.4.2.3
DIAGNOSTICS
7.4.2.4
HIGH-THROUGHPUT SCREENING
7.4.2.5
DRUG DISCOVERY
7.4.2.6
OTHER PROTEIN CHIP APPLICATIONS
7.5
TISSUE ARRAYS
7.5.1
INCREASING DEMAND FOR LARGE-SCALE VALIDATION OF BIOMARKERS TO SPUR GROWTH
7.5.2
GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023–2030 (THOUSAND UNITS)
7.6
CELL ARRAYS
7.6.1
EXPANDING USE OF CELL ARRAYS FOR HIGH-THROUGHPUT CELLULAR ANALYSIS AND DRUG SCREENING TO AID GROWTH
7.6.2
GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023–2030 (THOUSAND UNITS)
8
BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
171
8.1
INTRODUCTION
8.2
MICROARRAYS
8.2.1
WIDESPREAD ADOPTION OF MICROARRAYS IN GENOMIC AND PROTEOMIC RESEARCH TO FUEL MARKET
8.3
MICROFLUIDICS
8.3.1
GROWING DEMAND FOR DECENTRALIZED, POINT-OF-CARE DIAGNOSTICS, AND HIGH-THROUGHPUT SCREENING TOOLS TO DRIVE MARKET
9
BIOCHIPS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 6 Data Tables
177
9.1
INTRODUCTION
9.2
BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
9.2.1
RISING TREND OF PERSONALIZED AND PRECISION THERAPEUTICS TO EXPEDITE GROWTH
9.3
HOSPITALS & DIAGNOSTIC CENTERS
9.3.1
INCREASING HOSPITAL INVESTMENTS IN MOLECULAR PATHOLOGY TO EXPEDITE GROWTH
9.4
ACADEMIC & RESEARCH INSTITUTES
9.4.1
GROWING USE OF BIOCHIPS IN GENE-FUNCTION RELATIONSHIPS, PROTEIN NETWORKS, AND DISEASE MECHANISMS TO BOOST MARKET
9.5
CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.5.1
INCREASING TREND OF OUTSOURCING RESEARCH AND DEVELOPMENT ACTIVITIES TO PROMOTE GROWTH
9.6
OTHER END USERS
10
BIOCHIPS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 20 Countries | 241 Data Tables.
188
10.1
INTRODUCTION
10.2
NORTH AMERICA
10.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2
NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
10.2.3
US
10.2.3.1
PRESENCE OF PROMINENT COMPANIES AND HIGH CANCER PREVALENCE TO EXPEDITE GROWTH
10.2.4
CANADA
10.2.4.1
EXPANDING GENOMICS AND PRECISION MEDICINE INITIATIVES TO DRIVE MARKET
10.3
EUROPE
10.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2
EUROPE: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
10.3.3
GERMANY
10.3.3.1
ROBUST ECOSYSTEM OF BIOTECH STARTUPS AND MULTINATIONAL CORPORATIONS TO PROMOTE GROWTH
10.3.4
UK
10.3.4.1
INCREASING HEALTHCARE INVESTMENTS AND GENOMIC ADVANCEMENTS TO DRIVE MARKET
10.3.5
FRANCE
10.3.5.1
STRONG GOVERNMENT INITIATIVES IN BIOTECHNOLOGY, PRECISION MEDICINE, AND HEALTHCARE INNOVATIONS TO BOOST MARKET
10.3.6
ITALY
10.3.6.1
GROWING DEMAND FOR PRECISION MEDICINE TO SPUR GROWTH
10.3.7
SPAIN
10.3.7.1
INCREASING DEMAND FOR PERSONALIZED MEDICINE AND STRONG GOVERNMENTAL & INSTITUTIONAL SUPPORT TO PROPEL MARKET
10.3.8
NETHERLANDS
10.3.8.1
INCREASING EMPHASIS ON GENOMICS AND PERSONALIZED MEDICINE TO FAVOR GROWTH
10.3.9
REST OF EUROPE
10.4
ASIA PACIFIC
10.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2
ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
10.4.3
CHINA
10.4.3.1
RISING HEALTHCARE DEMAND TO SUPPORT GROWTH
10.4.4
JAPAN
10.4.4.1
INCREASING GERIATRIC POPULATION TO DRIVE MARKET
10.4.5
INDIA
10.4.5.1
STRONG GOVERNMENT SUPPORT FOR DOMESTIC BIOTECH MANUFACTURING TO FACILITATE GROWTH
10.4.6
AUSTRALIA
10.4.6.1
INCREASING ADVANCEMENTS IN BIOTECHNOLOGY TO SPUR GROWTH
10.4.7
SOUTH KOREA
10.4.7.1
INCREASING HEALTHCARE EXPENDITURE TO EXPEDITE GROWTH
10.4.8
THAILAND
10.4.8.1
RISING HEALTHCARE INVESTMENTS TO ACCELERATE GROWTH
10.4.9
NEW ZEALAND
10.4.9.1
INCREASING FOCUS ON EARLY DETECTION AND IMPROVING SURVIVAL RATES TO DRIVE MARKET
10.4.10
REST OF ASIA PACIFIC
10.5
LATIN AMERICA
10.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2
LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
10.5.3
BRAZIL
10.5.3.1
INCREASING DEMAND FOR PRECISION MEDICINE AND ADVANCEMENTS IN GENOMICS TO FOSTER GROWTH
10.5.4
MEXICO
10.5.4.1
RISING PREVALENCE OF CHRONIC AND INFECTIOUS CONDITIONS TO CONTRIBUTE TO GROWTH
10.5.5
REST OF LATIN AMERICA
10.6
MIDDLE EAST & AFRICA
10.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2
MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
10.6.3
GCC COUNTRIES
10.6.3.1
KINGDOM OF SAUDI ARABIA (KSA)
10.6.3.2
UNITED ARAB EMIRATES (UAE)
10.6.3.3
REST OF GCC COUNTRIES
10.6.4
REST OF MIDDLE EAST & AFRICA
11
COMPETITIVE LANDSCAPE
Unveil market dominators and emerging disruptors shaping competitive dynamics and future growth.
300
11.1
OVERVIEW
11.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3
REVENUE SHARE ANALYSIS, 2020–2024
11.4
MARKET SHARE ANALYSIS, 2024
11.4.1
GLOBAL MARKET SHARE ANALYSIS, 2024
11.4.2
US MARKET SHARE ANALYSIS, 2024
11.5
COMPANY VALUATION AND FINANCIAL METRICS
11.5.1
COMPANY VALUATION
11.5.2
FINANCIAL METRICS
11.6
BRAND/PRODUCT COMPARATIVE ANALYSIS
11.7
R&D EXPENDITURE OF KEY PLAYERS
11.8
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.8.1
STARS
11.8.2
EMERGING LEADERS
11.8.3
PERVASIVE PLAYERS
11.8.4
PARTICIPANTS
11.8.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.8.5.1
COMPANY FOOTPRINT
11.8.5.2
REGION FOOTPRINT
11.8.5.3
PRODUCT & SERVICE FOOTPRINT
11.8.5.4
TYPE FOOTPRINT
11.8.5.5
FABRICATION TECHNOLOGY FOOTPRINT
11.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.9.1
PROGRESSIVE COMPANIES
11.9.2
RESPONSIVE COMPANIES
11.9.3
DYNAMIC COMPANIES
11.9.4
STARTING BLOCKS
11.9.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
11.9.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.10
COMPETITIVE SCENARIO
11.10.1
PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS
11.10.2
DEALS
11.10.3
EXPANSIONS
11.10.4
OTHER DEVELOPMENTS
12
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
324
12.1
KEY PLAYERS
12.1.1
THERMO FISHER SCIENTIFIC INC.
12.1.1.1
BUSINESS OVERVIEW
12.1.1.2
PRODUCTS/SERVICES OFFERED
12.1.1.3
RECENT DEVELOPMENTS
12.1.1.4
MNM VIEW
12.1.2
ILLUMINA, INC.
12.1.3
AGILENT TECHNOLOGIES, INC.
12.1.4
F. HOFFMANN-LA ROCHE LTD
12.1.5
QIAGEN
12.1.6
BIO-RAD LABORATORIES, INC.
12.1.7
ABBOTT
12.1.8
STANDARD BIOTOOLS
12.1.9
10X GENOMICS
12.1.10
CEPHEID
12.1.11
BIOMÉRIEUX
12.1.12
REVVITY
12.1.13
DIASORIN S.P.A.
12.1.14
RANDOX LABORATORIES LTD.
12.1.15
OXFORD GENE TECHNOLOGY IP LIMITED
12.2
OTHER PLAYERS
12.2.1
MICRONIT B.V.
12.2.2
RAYBIOTECH, INC.
12.2.3
PHALANX BIOTECH GROUP
12.2.4
ARRAYIT CORPORATION
12.2.5
3DHISTECH LTD.
12.2.6
CREATIVE BIOARRAY
12.2.7
TISSUEARRAY.COM
12.2.8
IBIOCHIPS
12.2.9
CAPITALBIOTECH CO., LTD.
12.2.10
PEPPERPRINT GMBH
13
APPENDIX
403
13.1
DISCUSSION GUIDE
13.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3
CUSTOMIZATION OPTIONS
13.3.1
PRODUCT ANALYSIS
13.3.2
COMPANY INFORMATION
13.3.3
GEOGRAPHIC ANALYSIS
13.3.4
REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
13.3.5
COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
13.3.6
BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
13.3.7
ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
13.4
RELATED REPORTS
13.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
BIOCHIPS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
STANDARD CURRENCY CONVERSION RATES, 2021–2024 (UNIT OF USD)
TABLE 3
BIOCHIPS MARKET: RISK ASSESSMENT
TABLE 4
BIOCHIPS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8
BIOCHIPS MARKET: MAJOR PATENTS, 2022–2025
TABLE 9
IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSANDS)
TABLE 10
EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSANDS)
TABLE 11
AVERAGE SELLING PRICE TREND OF BIOCHIPS, BY KEY PLAYER, 2022–2024
TABLE 12
AVERAGE SELLING PRICE TREND OF DNA CHIPS, BY REGION, 2022–2024
TABLE 13
AVERAGE SELLING PRICE TREND FOR LAB-ON-A-CHIP, BY REGION, 2022–2024
TABLE 14
AVERAGE SELLING PRICE TREND OF PROTEIN CHIPS, BY REGION, 2022–2024
TABLE 15
BIOCHIPS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 16
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS, BY PRODUCT
TABLE 17
KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 18
KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET
TABLE 19
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 20
KEY PRODUCT-RELATED TARIFF EFFECTIVE BIOCHIPS
TABLE 21
NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
TABLE 22
ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
TABLE 23
EUROPE: IMPACT ON GERMANY AND UK DUE TO THE US TARIFFS
TABLE 24
LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
TABLE 25
BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2023–2030 (USD MILLION)
TABLE 26
BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
KEY PLAYERS PROVIDING BIOCHIP CONSUMABLES
TABLE 28
BIOCHIPS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
KEY PLAYERS PROVIDING BIOCHIP INSTRUMENTS
TABLE 30
BIOCHIPS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
KEY PLAYERS PROVIDING BIOCHIPS SOFTWARE & SERVICES
TABLE 32
BIOCHIPS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 34
DNA CHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023–2030 (THOUSAND UNITS)
TABLE 36
DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 37
KEY PLAYERS PROVIDING DNA CHIPS FOR GENE EXPRESSION
TABLE 38
DNA CHIPS MARKET FOR GENE EXPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
KEY PLAYERS PROVIDING DNA CHIPS FOR SNP GENOTYPING
TABLE 40
DNA CHIPS MARKET FOR SNP GENOTYPING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
KEY PLAYERS PROVIDING DNA CHIPS FOR CANCER DIAGNOSTICS & TREATMENT
TABLE 42
DNA CHIPS MARKET FOR CANCER DIAGNOSTICS & TREATMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
KEY PLAYERS PROVIDING DNA CHIPS FOR GENOMICS
TABLE 44
DNA CHIPS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
DNA CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
DNA CHIPS MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
DNA CHIPS MARKET FOR OTHER DNA CHIP APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
LAB-ON-A-CHIP MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023–2030 (THOUSAND UNITS)
TABLE 50
LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 51
KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR CLINICAL DIAGNOSTIC
TABLE 52
LAB-ON-A-CHIP MARKET FOR CLINICAL DIAGNOSTIC, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR GENOMICS
TABLE 54
LAB-ON-A-CHIP MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR IVD & POC
TABLE 56
LAB-ON-A-CHIP MARKET FOR IVD & POC, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
KEY PLAYERS PROVIDING LAB-ON-A-CHIP FOR PROTEOMICS
TABLE 58
LAB-ON-A-CHIP MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
LAB-ON-A-CHIP MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
LAB-ON-A-CHIP MARKET FOR OTHER LOAC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
PROTEIN CHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023–2030 (THOUSAND UNITS)
TABLE 63
PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 64
KEY PLAYERS PROVIDING PROTEIN CHIPS FOR PROTEOMICS
TABLE 65
PROTEIN CHIPS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
KEY PLAYERS PROVIDING PROTEIN CHIPS FOR EXPRESSION PROFILING
TABLE 67
PROTEIN CHIPS MARKET FOR EXPRESSION PROFILING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
KEY PLAYERS PROVIDING PROTEIN CHIPS FOR DIAGNOSTICS
TABLE 69
PROTEIN CHIPS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
KEY PLAYERS PROVIDING PROTEIN CHIPS FOR HIGH-THROUGHPUT SCREENING
TABLE 71
PROTEIN CHIPS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
PROTEIN CHIPS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
PROTEIN CHIPS MARKET FOR OTHER PROTEIN CHIP APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
KEY PLAYERS PROVIDING TISSUE ARRAYS
TABLE 75
TISSUE ARRAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023–2030 (THOUSAND UNITS)
TABLE 77
KEY PLAYERS PROVIDING CELL ARRAYS
TABLE 78
BIOCHIPS MARKET FOR CELL ARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023–2030 (THOUSAND UNITS)
TABLE 80
BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 81
KEY PLAYERS PROVIDING BIOCHIP MICROARRAYS
TABLE 82
BIOCHIPS MARKET FOR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
KEY PLAYERS PROVIDING MICROFLUIDICS
TABLE 84
BIOCHIPS MARKET FOR MICROFLUIDICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 86
BIOCHIPS MARKET FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
BIOCHIPS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
BIOCHIPS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
BIOCHIPS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
BIOCHIPS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
BIOCHIPS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 92
NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
TABLE 93
NORTH AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
NORTH AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 95
NORTH AMERICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 97
NORTH AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 98
NORTH AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 99
NORTH AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 100
NORTH AMERICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 101
US: KEY MACROECONOMIC INDICATORS
TABLE 102
US: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 103
US: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 104
US: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 105
US: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 106
US: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 107
US: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 108
US: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 109
CANADA: KEY MACROECONOMIC INDICATORS
TABLE 110
CANADA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 111
CANADA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 112
CANADA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 113
CANADA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 114
CANADA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 115
CANADA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 116
CANADA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 117
EUROPE: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
TABLE 118
EUROPE: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 120
EUROPE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 121
EUROPE: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 122
EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 123
EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 124
EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 125
EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 126
GERMANY: KEY MACROECONOMIC INDICATORS
TABLE 127
GERMANY: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 128
GERMANY: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 129
GERMANY: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 130
GERMANY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 131
GERMANY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 132
GERMANY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 133
GERMANY: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 134
UK: KEY MACROECONOMIC INDICATORS
TABLE 135
UK: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 136
UK: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 137
UK: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 138
UK: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 139
UK: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 140
UK: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 141
UK: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 142
FRANCE: KEY MACROECONOMIC INDICATORS
TABLE 143
FRANCE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 144
FRANCE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 145
FRANCE: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 146
FRANCE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 147
FRANCE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 148
FRANCE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 149
FRANCE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 150
ITALY: KEY MACROECONOMIC INDICATORS
TABLE 151
ITALY: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 152
ITALY: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 153
ITALY: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 154
ITALY: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 155
ITALY: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 156
ITALY: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 157
ITALY: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 158
SPAIN: KEY MACROECONOMIC INDICATORS
TABLE 159
SPAIN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 160
SPAIN: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 161
SPAIN: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 162
SPAIN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 163
SPAIN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 164
SPAIN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 165
SPAIN: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 166
NETHERLANDS: KEY MACROECONOMIC INDICATORS
TABLE 167
NETHERLANDS: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 168
NETHERLANDS: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 169
NETHERLANDS: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 170
NETHERLANDS: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 171
NETHERLANDS: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 172
NETHERLANDS: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 173
NETHERLANDS: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 174
REST OF EUROPE: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 175
REST OF EUROPE: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 176
REST OF EUROPE: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 177
REST OF EUROPE: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 178
REST OF EUROPE: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 179
REST OF EUROPE: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 180
REST OF EUROPE: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 181
ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
TABLE 182
ASIA PACIFIC: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 184
ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 185
ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 186
ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 187
ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 188
ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 189
ASIA PACIFIC: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 190
CHINA: KEY MACROECONOMIC INDICATORS
TABLE 191
CHINA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 192
CHINA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 193
CHINA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 194
CHINA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 195
CHINA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 196
CHINA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 197
CHINA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 198
JAPAN: KEY MACROECONOMIC INDICATORS
TABLE 199
JAPAN: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 200
JAPAN: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 201
JAPAN: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 202
JAPAN: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 203
JAPAN: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 204
JAPAN: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 205
JAPAN: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 206
INDIA: KEY MACROECONOMIC INDICATORS
TABLE 207
INDIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 208
INDIA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 209
INDIA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 210
INDIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 211
INDIA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 212
INDIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 213
INDIA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 214
AUSTRALIA: KEY MACROECONOMIC INDICATORS
TABLE 215
AUSTRALIA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 216
AUSTRALIA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 217
AUSTRALIA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 218
AUSTRALIA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 219
AUSTRALIA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 220
AUSTRALIA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 221
AUSTRALIA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 222
SOUTH KOREA: KEY MACROECONOMIC INDICATORS
TABLE 223
SOUTH KOREA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 224
SOUTH KOREA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 225
SOUTH KOREA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 226
SOUTH KOREA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 227
SOUTH KOREA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 228
SOUTH KOREA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 229
SOUTH KOREA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 230
THAILAND: KEY MACROECONOMIC INDICATORS
TABLE 231
THAILAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 232
THAILAND: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 233
THAILAND: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 234
THAILAND: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 235
THAILAND: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 236
THAILAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 237
THAILAND: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 238
NEW ZEALAND: KEY MACROECONOMIC INDICATORS
TABLE 239
NEW ZEALAND: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 240
NEW ZEALAND: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 241
NEW ZEALAND: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 242
NEW ZEALAND: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 243
NEW ZEALAND: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 244
NEW ZEALAND: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 245
NEW ZEALAND: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 246
REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 247
REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 248
REST OF ASIA PACIFIC: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 249
REST OF ASIA PACIFIC: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 250
REST OF ASIA PACIFIC: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 251
REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 252
REST OF ASIA PACIFIC: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 253
LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
TABLE 254
LATIN AMERICA: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 255
LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 256
LATIN AMERICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 257
LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 258
LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 259
LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 260
LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 261
LATIN AMERICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 262
BRAZIL: KEY MACROECONOMIC INDICATORS
TABLE 263
BRAZIL: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 264
BRAZIL: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 265
BRAZIL: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 266
BRAZIL: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 267
BRAZIL: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 268
BRAZIL: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 269
BRAZIL: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 270
MEXICO: KEY MACROECONOMIC INDICATORS
TABLE 271
MEXICO: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 272
MEXICO: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273
MEXICO: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 274
MEXICO: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 275
MEXICO: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 276
MEXICO: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 277
MEXICO: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 278
REST OF LATIN AMERICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 279
REST OF LATIN AMERICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
REST OF LATIN AMERICA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281
REST OF LATIN AMERICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 282
REST OF LATIN AMERICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 283
REST OF LATIN AMERICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 284
REST OF LATIN AMERICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 285
MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023–2030 (THOUSAND UNITS)
TABLE 286
MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 287
MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 288
MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 289
MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 290
MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 291
MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 292
MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 293
MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 294
GCC COUNTRIES: BIOCHIPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 295
GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 296
GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 297
GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 298
GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 299
GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 300
GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 301
GCC COUNTRIES: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 302
KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS
TABLE 303
KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 304
KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 305
KINGDOM OF SAUDI ARABIA (KSA): DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 306
KINGDOM OF SAUDI ARABIA (KSA): LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 307
KINGDOM OF SAUDI ARABIA (KSA): PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 308
KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 309
KINGDOM OF SAUDI ARABIA (KSA): BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 310
UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS
TABLE 311
UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 312
UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 313
UNITED ARAB EMIRATES (UAE): DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 314
UNITED ARAB EMIRATES (UAE): LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 315
UNITED ARAB EMIRATES (UAE): PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 316
UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 317
UNITED ARAB EMIRATES (UAE): BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 318
REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 319
REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 320
REST OF GCC COUNTRIES: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 321
REST OF GCC COUNTRIES: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 322
REST OF GCC COUNTRIES: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 323
REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 324
REST OF GCC COUNTRIES: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325
REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
TABLE 326
REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327
REST OF MIDDLE EAST & AFRICA: DNA CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 328
REST OF MIDDLE EAST & AFRICA: LAB-ON-A-CHIP MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 329
REST OF MIDDLE EAST & AFRICA: PROTEIN CHIPS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 330
REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 331
REST OF MIDDLE EAST & AFRICA: BIOCHIPS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 332
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOCHIPS MARKET, 2022–2024
TABLE 333
GLOBAL BIOCHIPS MARKET: DEGREE OF COMPETITION
TABLE 334
US BIOCHIPS MARKET: DEGREE OF COMPETITION
TABLE 335
BIOCHIPS MARKET: REGION FOOTPRINT
TABLE 336
BIOCHIPS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 337
BIOCHIPS MARKET: TYPE FOOTPRINT
TABLE 338
BIOCHIPS MARKET: FABRICATION TECHNOLOGY FOOTPRINT
TABLE 339
BIOCHIPS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 340
BIOCHIPS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 341
BIOCHIPS MARKET: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 342
BIOCHIPS MARKET: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 343
BIOCHIPS MARKET: EXPANSIONS, JANUARY 2022−SEPTEMBER 2025
TABLE 344
BIOCHIPS MARKET: OTHERS, JANUARY 2022–SEPTEMBER 2025
TABLE 345
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 346
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 347
THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 348
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 349
ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 350
ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 351
ILLUMINA, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025
TABLE 352
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 353
AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 354
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025
TABLE 355
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
TABLE 356
AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025
TABLE 357
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 358
F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
TABLE 359
F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 360
QIAGEN: COMPANY OVERVIEW
TABLE 361
QIAGEN: PRODUCTS/SERVICES OFFERED
TABLE 362
QIAGEN: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 363
QIAGEN: DEALS, JANUARY 2022–SEPTEMBER 2025
TABLE 364
QIAGEN: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
TABLE 365
QIAGEN: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025
TABLE 366
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 367
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 368
ABBOTT: COMPANY OVERVIEW
TABLE 369
ABBOTT: PRODUCTS/SERVICES OFFERED
TABLE 370
ABBOTT: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 371
STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 372
STANDARD BIOTOOLS: PRODUCTS/SERVICES OFFERED
TABLE 373
STANDARD BIOTOOLS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 374
STANDARD BIOTOOLS INC.: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 375
STANDARD BIOTOOLS INC.: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025
TABLE 376
10X GENOMICS: COMPANY OVERVIEW
TABLE 377
10X GENOMICS: PRODUCTS/SERVICES OFFERED
TABLE 378
10X GENOMICS: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 379
10X GENOMICS: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 380
10X GENOMICS: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025
TABLE 381
CEPHEID: COMPANY OVERVIEW
TABLE 382
CEPHEID: PRODUCTS/SERVICES OFFERED
TABLE 383
CEPHEID: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 384
CEPHEID: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 385
CEPHEID: OTHER DEVELOPMENTS, JANUARY 2022−SEPTEMBER 2025
TABLE 386
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 387
BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
TABLE 388
BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 389
BIOMÉRIEUX: DEALS, JANUARY 2022–SEPTEMBER 2025
TABLE 390
REVVITY: COMPANY OVERVIEW
TABLE 391
REVVITY: PRODUCTS/SERVICES OFFERED
TABLE 392
REVVITY: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 393
DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 394
DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED
TABLE 395
RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
TABLE 396
RANDOX LABORATORIES LTD.: PRODUCTS/SERVICES OFFERED
TABLE 397
RANDOX LABORATORIES LTD.: PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−SEPTEMBER 2025
TABLE 398
RANDOX LABORATORIES LTD.: DEALS, JANUARY 2022−SEPTEMBER 2025
TABLE 399
RANDOX LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025
TABLE 400
OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW
TABLE 401
OXFORD GENE TECHNOLOGY IP LIMITED: PRODUCTS/SERVICES OFFERED
TABLE 402
MICRONIT B.V.: COMPANY OVERVIEW
TABLE 403
RAYBIOTECH, INC.: COMPANY OVERVIEW
TABLE 404
PHALANX BIOTECH GROUP: COMPANY OVERVIEW
TABLE 405
ARRAYIT CORPORATION: COMPANY OVERVIEW
TABLE 406
3DHISTECH LTD.: COMPANY OVERVIEW
TABLE 407
CREATIVE BIOARRAY: COMPANY OVERVIEW
TABLE 408
TISSUEARRAY.COM: COMPANY OVERVIEW
TABLE 409
IBIOCHIPS: COMPANY OVERVIEW
TABLE 410
CAPITALBIOTECH CO., LTD.: COMPANY OVERVIEW
TABLE 411
PEPPERPRINT GMBH: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
BIOCHIPS MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
BIOCHIPS MARKET: RESEARCH DESIGN
FIGURE 3
PRIMARY SOURCES
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE)
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 7
SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8
REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC INC.
FIGURE 9
REVENUE ANALYSIS OF TOP FIVE COMPANIES: BIOCHIPS MARKET (2024)
FIGURE 10
DEMAND-SIDE MARKET ESTIMATION FOR BIOCHIPS
FIGURE 11
CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOCHIPS MARKET (2025–2030)
FIGURE 12
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 13
TOP-DOWN APPROACH
FIGURE 14
BOTTOM-UP APPROACH
FIGURE 15
MARKET DATA TRIANGULATION METHODOLOGY
FIGURE 16
BIOCHIPS MARKET, BY PRODUCTS & SERVICES, 2025 VS. 2030 (USD MILLION)
FIGURE 17
BIOCHIPS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 18
DNA CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 19
LAB-ON-A-CHIP MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 20
PROTEIN CHIPS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 21
BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 22
BIOCHIPS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 23
GEOGRAPHIC SNAPSHOT OF BIOCHIPS MARKET
FIGURE 24
INCREASING INCIDENCE OF CHRONIC CONDITIONS TO FUEL MARKET
FIGURE 25
CONSUMABLES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024
FIGURE 26
ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 27
CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 28
EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 29
BIOCHIPS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 30
BIOCHIPS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31
BIOCHIPS MARKET: PATENT ANALYSIS, JANUARY 2014–OCTOBER 2025
FIGURE 32
TOP APPLICANTS FOR BIOCHIPS PATENTS, BY JURISDICTION, JANUARY 2014–OCTOBER 2025
FIGURE 33
AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP, BY KEY PLAYER, 2024
FIGURE 34
AVERAGE SELLING PRICE FOR DNA CHIPS AND LAB-ON-A-CHIP, BY REGION, 2024
FIGURE 35
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BIOCHIPS, BY PRODUCT
FIGURE 36
KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 37
AI-USE CASES
FIGURE 38
BIOCHIPS MARKET: ECOSYSTEM MARKET MAP
FIGURE 39
BIOCHIPS MARKET: VALUE CHAIN ANALYSIS
FIGURE 40
BIOCHIPS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 41
REVENUE SHIFT AND NEW REVENUE POCKETS FOR BIOCHIPS MARKET
FIGURE 42
BIOCHIPS MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 43
NORTH AMERICA: BIOCHIPS MARKET SNAPSHOT
FIGURE 44
ASIA PACIFIC: BIOCHIPS MARKET SNAPSHOT
FIGURE 45
REVENUE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2020−2024
FIGURE 46
MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
FIGURE 47
RANKING OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
FIGURE 48
US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOCHIPS MARKET, 2024
FIGURE 49
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 50
EV/EBITDA OF KEY VENDORS
FIGURE 51
BIOCHIPS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 52
R&D EXPENDITURE OF KEY PLAYERS IN BIOCHIPS MARKET, 2022−2024
FIGURE 53
BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 54
BIOCHIPS MARKET: COMPANY FOOTPRINT
FIGURE 55
BIOCHIPS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 56
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 57
ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
FIGURE 58
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 59
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
FIGURE 60
QIAGEN: COMPANY SNAPSHOT (2024)
FIGURE 61
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 62
ABBOTT: COMPANY SNAPSHOT (2024)
FIGURE 63
STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024)
FIGURE 64
10X GENOMICS: COMPANY SNAPSHOT (2024)
FIGURE 65
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
FIGURE 66
REVVITY: COMPANY SNAPSHOT (2024)
FIGURE 67
DIASORIN S.P.A.: COMPANY SNAPSHOT (2024)
Methodology
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biochips Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Biochips Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Biochips Market